Nneka Nwachukwu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nneka Nwachukwu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Attah1 shared publication
- Ashley Hagiya
Department of Pathology, Hematopathology Section Keck School of Medicine of the University of Southern California Los Angeles California USA
1 shared publication - Caitlin O'NEill
Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA
1 shared publication - Casey Lee O’connell
Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California
1 shared publication - Fuad El Rassi
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
1 shared publication Justin Yoo
1 shared publication
Latest Publications
- Open Access
- 25 August 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Maternal and fetal outcomes in sickle cell disease: impact of anemia and prophylactic transfusion
- 25 August 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (4)
Open AccessMaternal and fetal outcomes in sickle cell disease: impact of anemia and prophylactic transfusion
- Open Access
- 13 December 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (4) , 594-600
Clinical and pathological features of clonal cytopenia of undetermined significance presenting with isolated thrombocytopenia (CCUS‐IT)
Background: Clonal cytopenia of undetermined significance (CCUS) is defined as somatic mutations of myeloid malignancy-associated genes in the blood or bone marrow with one or more persistent unexplained cytopenias that do not meet diagnostic criteria for a defined myeloid neoplasm. CCUS with isolated thrombocytopenia (CCUS-IT) is rare.Methods: This is a retrospective case series of patients with prolonged isolated thrombocytopenia, a pathogenic mutation on a myeloid molecular panel, and a bone marrow biopsy with morphologic atypia below the WHO-defined diagnostic threshold for dysplasia.Results: Five male patients were identified with a median age at CCUS-IT diagnosis of 61 years (56-74). Median duration of thrombocytopenia prior to CCUS-IT diagnosis was 4 years (3-12), and median platelet count at CCUS-IT diagnosis was 41 x 10(3)/mu L (26-80). All patients had megakaryocytic hyperplasia and megakaryocytes with hyperchromasia and high nuclear-cytoplasmic ratio. Pathogenic SRSF2 mutations were identified in all 5 patients with median variant allele frequency of 36% (28%-50%). Three patients were treated with IVIg and/or steroids with no response; one of three responded to thrombopoietin receptor agonists. Three patients progressed to MDS and one to AML.Discussion: We describe the clinicopathological features of CCUS-IT which can mimic immune thrombocytopenia.
- 13 December 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (4) , 594-600
Open AccessClinical and pathological features of clonal cytopenia of undetermined significance presenting with isolated thrombocytopenia (CCUS‐IT)
Background: Clonal cytopenia of undetermined significance (CCUS) is defined as somatic mutations of myeloid malignancy-associated genes in the blood or bone marrow with one or more persistent unexplained cytopenias that do not meet diagnostic criteria for a defined myeloid neoplasm. CCUS with isolated thrombocytopenia (CCUS-IT) is rare.Methods: This is a retrospective case series of patients with prolonged isolated thrombocytopenia, a pathogenic mutation on a myeloid molecular panel, and a bone marrow biopsy with morphologic atypia below the WHO-defined diagnostic threshold for dysplasia.Results: Five male patients were identified with a median age at CCUS-IT diagnosis of 61 years (56-74). Median duration of thrombocytopenia prior to CCUS-IT diagnosis was 4 years (3-12), and median platelet count at CCUS-IT diagnosis was 41 x 10(3)/mu L (26-80). All patients had megakaryocytic hyperplasia and megakaryocytes with hyperchromasia and high nuclear-cytoplasmic ratio. Pathogenic SRSF2 mutations were identified in all 5 patients with median variant allele frequency of 36% (28%-50%). Three patients were treated with IVIg and/or steroids with no response; one of three responded to thrombopoietin receptor agonists. Three patients progressed to MDS and one to AML.Discussion: We describe the clinicopathological features of CCUS-IT which can mimic immune thrombocytopenia.